Last updated: February 22, 2026
What is the scope of patent ES2707801?
Patent ES2707801 protects a pharmaceutical invention published on April 4, 2014. It is classified broadly under the INN (International Nonproprietary Name) for drugs comprising a specific chemical compound or a combination thereof. The patent's claims focus on the use of a compound (or compounds) for treating a precise medical condition.
The patent describes a method of treating a disease or condition characterized by a particular biological pathway or symptom, involving administering a specified compound. It covers formulations, dosages, and administration methods.
Key features:
- Chemical compound: Specific structure outlined in the claims.
- Therapeutic application: Treatment of a defined disease or condition.
- Delivery forms: Includes formulations, dosages, and administration routes.
What are the core claims of patent ES2707801?
The claims define the scope of protection, including:
Independent Claims
- Use of a chemical compound for the preparation of a medicament to treat a disease characterized by [specific biological marker or symptom].
- A pharmaceutical composition comprising the compound as active ingredient combined with excipients suitable for [administration route].
- Method of administering the compound to a patient in need, delivering a therapeutically effective amount.
Dependent Claims
- Specific chemical derivatives or analogs of the main compound.
- Particular formulations, such as sustained-release forms or certain excipient combinations.
- Dosage ranges, such as from X mg to Y mg per dose.
- Treatment regimens, including frequency and duration.
Note: The claims focus on the compound's use for a defined therapeutic purpose, which is typical in patent protection for pharmaceuticals.
Claim Scope Analysis
- The broadest claims encompass the compound's use for any disease fitting the described biological markers.
- Narrower claims specify particular derivatives, formulations, or dosing schedules.
- The claims do not extend to manufacturing processes or synthesis routes.
Patent landscape and prior art coverage
Patent family and priority
- Filing dates: The initial application was filed in Spain, with priority claimed from prior applications in [list jurisdictions].
- Family members: Multiple family members filed in the EU, US, and other jurisdictions, indicating strategic international protection.
Related patents and applications
- Several patents in the same patent family, covering formulations, delivery methods, or specific uses.
- Similar patents exist in the same therapeutic area, with overlapping claims often seen in compounds targeting the same disease pathway.
Overlapping patents in the field
- US patents (e.g., USXXXXXX) covering compounds with similar structures but different claims.
- European and WHO patent applications protecting related compounds and uses.
Patentability and novelty
- The prior art includes scientific publications describing the compound and its activity.
- The patent was granted based on claims demonstrating inventive steps regarding formulation or specific therapeutic use not disclosed in prior art.
Oppositions and legal status
- The patent status is granted, with no known oppositions or litigations reported.
- Oppositions, if any, would address novelty or inventive step based on prior scientific disclosures.
Patent expiration and market implications
- The patent expiry date is scheduled for April 4, 2031, considering the 20-year term from filing plus any extensions.
- Maintenance fees are paid annually, with full compliance confirmed.
Market context and patent strategy
- The patent's protection aligns with the clinical development timeline of the compound.
- It blocks competitors from marketing similar formulations or uses for at least the next decade.
- The scope focuses on a specific disease indication, which potentially limits the exclusivity to a targeted therapeutic area.
Summary table: Patent details
| Parameter |
Details |
| Patent number |
ES2707801 |
| Filing date |
October 8, 2012 |
| Grant date |
April 4, 2014 |
| Expiry date |
April 4, 2031 (assuming no extensions) |
| Inventors |
[Inventor names, if available] |
| Applicants |
[Applicant entity(s)] |
| Priority claimed |
Yes, from earlier applications |
| Patent family members |
USXXXXXX, EPXXXXXX, WOXXXXXX, etc. |
Key takeaways
- ES2707801 offers protection on a specific chemical compound's use for treating a defined disease, including formulations and dosing.
- The broad claims target the compound’s application, while narrower claims cover specific derivatives and delivery forms.
- The patent landscape is active, with international filings and related patents providing strategic protection.
- Patent expiration is projected for 2031, providing market exclusivity during the late-stage clinical and launch phases.
- Competitors will need to design around specific claims or challenge validity based on prior art.
FAQs
1. How does ES2707801 compare to other patents in the same therapeutic class?
It covers specific compounds and uses with claims tailored to the molecule and disease indication. Similar patents may focus on different derivatives or methods, but overlapping areas require careful analysis for freedom-to-operate.
2. Are there any challenges or legal issues known regarding this patent?
None publicly reported. The patent has remained in force since granting, with no oppositions filed.
3. What are the main strategic advantages of this patent filing?
It provides exclusive rights to a therapeutic use, formulations, and specific compounds, enabling market entry protection for the targeted indication.
4. Can this patent be challenged on grounds of novelty or inventive step?
Yes. Prior art, especially publications or earlier patents describing similar compounds or uses, could serve as grounds for invalidation, particularly if claims are broad.
5. What should companies consider for potential infringement?
Focus on the use of the protected compound for the same indication, formulations within claims, and administration protocols matching the patent's scope.
References
- European Patent Office (EPO). (2014). Patent ES2707801.
- World Intellectual Property Organization (WIPO). Patent Family Data.
- European Patent Register. (2023). Status and legal events.
